These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30674687)

  • 41. [The disease burden of human papillomavirus in men is substantial and can potentially be prevented].
    Kiellberg Larsen H; Kofoed K; Sand C
    Ugeskr Laeger; 2013 Feb; 175(6):349-53. PubMed ID: 23402241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human papillomavirus-related disease in men: not just a women's issue.
    Palefsky JM
    J Adolesc Health; 2010 Apr; 46(4 Suppl):S12-9. PubMed ID: 20307839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPV not just a young woman's problem.
    Vogel L
    CMAJ; 2017 Mar; 189(10):E416-E417. PubMed ID: 28385825
    [No Abstract]   [Full Text] [Related]  

  • 45. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
    Forcier M; Musacchio N
    Dermatol Ther; 2010; 23(5):458-76. PubMed ID: 20868401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.
    Kim JJ; Simms KT; Killen J; Smith MA; Burger EA; Sy S; Regan C; Canfell K
    PLoS Med; 2021 Mar; 18(3):e1003534. PubMed ID: 33705382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    Ginindza TG; Sartorius B; Dlamini X; Östensson E
    PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beyond cervical cancer: burden of other HPV-related cancers among men and women.
    Chaturvedi AK
    J Adolesc Health; 2010 Apr; 46(4 Suppl):S20-6. PubMed ID: 20307840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Nine-valent HPV vaccine - new generation of HPV vaccine].
    Fait T; Dvořák V; Pilka R
    Ceska Gynekol; 2015 Dec; 80(6):397-400. PubMed ID: 26741152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis.
    Wangu Z; Hsu KK
    Hum Vaccin Immunother; 2016 Jun; 12(6):1357-62. PubMed ID: 27217191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The first vaccine against cancer: the human papillomavirus vaccine].
    Bősze P
    Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidemiology and burden of HPV-related disease.
    Serrano B; Brotons M; Bosch FX; Bruni L
    Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():14-26. PubMed ID: 29037457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.
    Bresse X; Adam M; Largeron N; Roze S; Marty R
    Hum Vaccin Immunother; 2013 Apr; 9(4):823-33. PubMed ID: 23563511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
    Smith LM; Strumpf EC; Kaufman JS; Lofters A; Schwandt M; Lévesque LE
    Pediatrics; 2015 May; 135(5):e1131-40. PubMed ID: 25917991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
    Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
    J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ten Years of Human Papillomavirus Vaccination in the United States.
    Markowitz LE; Gee J; Chesson H; Stokley S
    Acad Pediatr; 2018 Mar; 18(2S):S3-S10. PubMed ID: 29502635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018).
    Cocchio S; Prandi GM; Furlan P; Bertoncello C; Fonzo M; Saia M; Baldovin T; Baldo V
    BMC Infect Dis; 2020 Nov; 20(1):857. PubMed ID: 33208109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
    Liao CI; Francoeur AA; Kapp DS; Caesar MAP; Huh WK; Chan JK
    JAMA Netw Open; 2022 Mar; 5(3):e222530. PubMed ID: 35294540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?
    Isaranuwatchai W; Graham DM; Siu LL; Hoch JS
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):763-5. PubMed ID: 25095728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.